Abstract
V˙/Q˙ mismatch and the loss of hypoxic pulmonary vasoconstriction play a pivotal role in the pathophysiology of COVID-19 respiratory distress.1,2 Dihydropyridine calcium channel blockers (CCBs), frequently prescribed first-line antihypertensive agents, have the potential to disrupt hypoxic pulmonary vasoconstriction3 and worsen V̇/Q̇ mismatch that leads to profound hypoxemia in patients with pulmonary disease.4 We hypothesized that CCBs would be associated with worse respiratory failure in patients with COVID-19.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
